Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life

被引：0

作者：

Pugnet, G. ^{[1
,2
]}

Pagnoux, C. ^{[3
]}

Terrier, B. ^{[1
]}

Perrodeau, E. ^{[4
]}

Puechal, X. ^{[1
]}

Karras, A. ^{[5
,16
]}

Khouatra, C. ^{[6
]}

Aumaitre, O. ^{[7
]}

Cohen, P. ^{[1
]}

Maurier, F. ^{[8
]}

Decaux, O. ^{[9
]}

Ninet, J. ^{[10
]}

Gobert, P. ^{[11
]}

Quemeneur, T. ^{[12
,13
]}

Blanchard-Delaunay, C. ^{[14
]}

Godmer, P. ^{[15
]}

Carron, P. -L. ^{[16
]}

Hatron, P. -Y. ^{[17
]}

Limal, N. ^{[18
]}

Hamidou, M. ^{[19
]}

Ducret, M. ^{[20
]}

Daugas, E. ^{[21
]}

Papo, T. ^{[22
]}

Bonnotte, B. ^{[23
,24
]}

Mahr, A. ^{[25
]}

Ravaud, P. ^{[4
]}

Mouthon, L. ^{[1
]}

Guillevin, L. ^{[1
]}

机构：

[1] Univ Paris 05, AP HP, Hop Cochin, Natl Referral Ctr Rare System Autoimmune Dis, Paris, France

[2] Toulouse Univ Hosp, Dept Internal Med, Toulouse, France

[3] Univ Toronto, Mt Sinai Hosp, Dept Rheumatol, Toronto, ON M5G 1X5, Canada

[4] Univ Paris 05, Hop Hotel Dieu, AP HP, Ctr Epidemiol Clin,INSERM,U738, Paris, France

[5] Univ Paris 05, Hop Europeen Georges Pompidou, Unite Nephrol, Paris, France

[6] Hop Univ Louis Pradel, Serv Pneumol, Ctr Reference Malad Pulm Rares, Lyon, France

[7] Hop Gabriel Montpied, Ctr Hosp Univ, Div internal Med, Clermont Ferrand, France

[8] Hop Prives Metz, Dept Internal Med, Metz, France

[9] Univ Rennes 1, Hop Sud, Hop Univ Rennes, Dept Med Interne,IGDR,UMR 6290, Rennes, France

[10] Hop Edouard Herriot, Dept Nephrol & Internal Med, Lyon, France

[11] Hop Gen Henri Duffaut, Serv Med Interne & Nephrol, Avignon, France

[12] Ctr Hosp Valenciennes, Dept Nephrol, Valenciennes, France

[13] Ctr Hosp Valenciennes, Dept Med Interne, Valenciennes, France

[14] Hop Niort, Serv Med Interne, Niort, France

[15] Ctr Hosp Bretagne Atlantique Vannes, Dept Internal Med, Vannes, France

[16] Ctr Hosp Univ Grenoble, Serv Nephrol Dialyse & Transplantat, Grenoble, France

[17] Univ Lille Nord France, Ctr Hosp Univ Lille, Hop Claude Huriez, Serv Med Interne,Ctr Natl Reference Sclerodermie, Lille, France

[18] Hop Henri Mondor, AP HP, Serv Med Interne, Ctr Reference Labellise Prise Charge Cytopenies A, F-94010 Creteil, France

[19] Ctr Hosp Univ Hotel Dieu, Dept Med Interne, Nantes, France

[20] Ctr Hosp Annecy, Serv Nephrol, Annecy Le Vieux, France

[21] Univ Paris Diderot, Hop Bichat, Serv Nephrol, INSERM,U699,Dept Hosp Univ FIRE, Paris, France

[22] Hop Xavier Bichat, Dept Med Interne, Paris, France

[23] Univ Bourgogne, Ctr Hosp Univ Dijon, Serv Med Interne & Immunol Clin, IFR100, Dijon, France

[24] INSERM, UMR 1098, Besancon, France

[25] Univ Paris 07, Hosp St Louis, Serv Med Interne, F-75221 Paris 05, France

来源：

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2016年 / 34卷 / 03期

关键词：

ANCA-associated vasculitis; maintenance therapy; rituximab; azathioprine; health-related quality of life; CONSENSUS CONFERENCE; SINGLE-CENTER; SHORT-FORM; GRANULOMATOSIS; CYCLOPHOSPHAMIDE; NOMENCLATURE; SF-36;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. To investigate the effects on health-related quality of life (HRQOL) and functional capability of rituximab vs azathioprine for ANCA-associated vasculitis (AAV) maintenance therapy. Methods. In a 24-month phase III randomised-controlled trial, 115 patients over time received rituximab or azathioprine for AAV maintenance therapy. Mean changes of 36-item Short-form Health Survey (SF-36) and Health Assessment Questionnaire (HAQ) scores from baseline were analysed. Results. Mean improvements of HAQ scores, from baseline to month 24 were significantly better for the rituximab (0.16 points lower) than the azathioprine group (p=0.038). As demonstrated by SF-36, study patients' baseline HRQOL was significantly impaired compared with age-and sex-matched US norms. At month 24, mean changes from baseline of SF-36 physical component score tended to be better for the rituximab group (+3.95 points, p=0.067) whereas mean changes from baseline of the SF-36 mental component score were significantly better for the azathioprine group (+4.23 points, p=0.041). Conclusion. Azathioprine-treated patients' for AAV maintenance therapy showed a decline in physical abilities when compared to RTX at M24 in the MAINRITSAN trial.

引用

页码：S54 / S59

页数：6

共 50 条

[41] HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH ANCA VASCULITIS
Riogh, Eithne Nic An
Gogarty, Eoin
Reedy, Brian
Verrelli, Alyssa
Elhassan, Elhussein
Scott, Jennifer
White, Arthur
Little, Mark
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I146 - I146
[42] A RANDOMIZED, CONTROLLED TRIAL OF RITUXIMAB VERSUS AZATHIOPRINE AFTER INDUCTION OF REMISSION WITH RITUXIMAB FOR PATIENTS WITH ANCA-ASSOCIATED VASCULITIS AND RELAPSING DISEASE
Smith, R.
Jayne, D.
Merkel, P. A.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 19 - 20
[43] EFFICACY OF ULTRA-LOW DOSE RITUXIMAB FOR REMISSION MAINTENANCE THERAPY IN ANCA-ASSOCIATED VASCULITIS
Campaniello, D.
Treppo, E.
D'onofrio, B.
Franchi, G.
Berti, A.
Iorio, L.
Bortolotti, R.
Montecucco, C.
Monti, S.
Quartuccio, L.
Doria, A.
Schiavon, F.
Padoan., R.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 710 - 710
[44] Defining a Therapeutic Window for Rituximab Maintenance Therapy in ANCA-Associated Vasculitis A Longitudinal Observational Study
Springer, Jason Michael
Funk, Ryan S.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 (05) : 215 - 217
[45] Factors Predictive of ANCA-Associated Vasculitis Relapse in Patients Given Rituximab-Maintenance Therapy
Terrier, Benjamin
Pagnoux, Christian
Geri, Guillaume
Karras, Alexandre
Khouatra, Chahera
Aumaitre, Olivier
Cohen, Pascal
Maurier, Francois
Decaux, Olivier
Desmurs-Clavel, Helene
Gobert, Pierre
Quemeneur, Thomas
Blanchard-Delaunay, Claire
Godmer, Pascal
Puechal, Xavier
Mouthon, Luc
ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S779 - S779
[46] A RANDOMIZED, CONTROLLED TRIAL OF RITUXIMAB VERSUS AZATHIOPRINE AFTER INDUCTION OF REMISSION WITH RITUXIMAB FOR PATIENTS WITH ANCA-ASSOCIATED VASCULITIS AND RELAPSING DISEASE
Smith, Rona
Jayne, David
Merkel, Peter
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 2185 - 2185
[47] Rituximab in ANCA-associated vasculitis: fewer infusions or ultra low-dose maintenance therapy?
Moiseev, Sergey V.
Bulanov, Nikolai M.
Zykova, Anastasiia S.
Novikov, Pavel I.
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (09) : E99 - +
[48] A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease
Smith, Rona
Jayne, David
Merkel, Peter
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[49] The Effect of Treatment with the Complement C5a Receptor Inhibitor Avacopan on Health-Related Quality of Life in ANCA-Associated Vasculitis
Strand, Vibeke
Bekker, Pirow
Yue, Huibin
Jayne, David R. W.
Merkel, Peter
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1990 - 1992
[50] Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives
Treppo, Elena
Binutti, Marco
Agarinis, Roberto
De Vita, Salvatore
Quartuccio, Luca
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (17)

← 1 2 3 4 5 →